Abstract, Poster, and Oral Presentation Resources/Opportunities

Abstract Writing Resources

If you intend on presenting your research at a meeting, please let Katie Dunn know before you submit your abstract so she can track research presentations by emailing her at Katie.Dunn@tufts.edu.

Before starting to work on your abstract make sure you have read through the meeting’s abstract guidelines.  The information below is standard guidance on how to write an abstract however, it will be most helpful to people submitting to ADEA or the AADR/IADR meetings.

Writing an Abstract Helpful Links:

Writing a Publication:
Creating a Poster/Oral Presentation:
Presentation Opportunities
ClinicalTrials.gov Posting Requirements and Regulations:

As of January 18, 2017, ClinicalTrials.gov registration is required for trials that meet the Final Rule definition of an Applicable Clinical Trials (ACTs) include the following:

  • Study type= Interventional;

Note: If the study is a pediatric postmarket surveillance of a device product, it meets the definition of an applicable device clinical trial

  • Studies a FDA regulated drug or device product;
  • Study phase ≠ Phase 1 (drug and biological products);
  • Primary purpose ≠ device feasibility (device products); and
  • Any of the following apply:
    • Facility location= US (or US territory);
    • Has US FDA IND or IDE number; or
    • Product is manufactured in and exported from the US

Many journals also require clinical trials to be posted on ClincialTrials.gov, regardless of federal reporting requirements. When initiating a study, please consider what publication you may want to submit results to, in order to ensure this potential requirement is met.

Reporting requirements for Applicable Clinical Trials:
  • Must be registered on ClinicalTrials.gov no later than 21 days after enrollment of the 1st participant
  • Study record must be updated on ClinicalTrials.gov at least once every 12 months
    • Changes in recruitment status or primary completion date must be updated within 30 days
  • Summary results (including AE information) must be submitted no later than 1 year after the study’s primary completion date

In addition, if a study will be registered on ClinicalTrials.gov, this must be disclosed in the Informed Consent Form (ICF) for the study.

For any questions, please contact Nicolette.Kafasis@tufts.edu who can assist with submitting your study to https://clinicaltrials.gov/ under the TUSDM account and setting you up with a username and password.

If you intend on presenting your research at a meeting, please let Katie Dunn know so she can track research presentations by emailing her at Katie.Dunn@tufts.edu.